Novel Acylguanidine-Based Inhibitor of HIV-1.

In vitro functional assessment of natural HIV-1 group M Vpu sequences using a universal priming approach. J Virol Methods (2016) 0.75

Various plus unique: Viral protein U as a plurifunctional protein for HIV-1 replication. Exp Biol Med (Maywood) (2017) 0.75

Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70

Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature (2008) 14.99

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol (1996) 11.91

The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe (2008) 9.27

A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell (1998) 5.89

Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol (1992) 5.05

Amiloride and its analogs as tools in the study of ion transport. J Membr Biol (1988) 4.65

Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe (2009) 3.58

Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs. J Virol (1990) 3.42

Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. J Virol (1992) 3.06

Construction and in vitro properties of HIV-1 mutants with deletions in "nonessential" genes. AIDS Res Hum Retroviruses (1994) 2.72

CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef. J Virol (1996) 2.61

Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells. FEBS Lett (1996) 2.43

Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther (1999) 2.34

Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog (2010) 2.12

Mutual functional destruction of HIV-1 Vpu and host TASK-1 channel. Mol Cell (2004) 2.05

The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J Virol (1996) 2.01

Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. J Virol (2013) 1.93

Correlation of the structural and functional domains in the membrane protein Vpu from HIV-1. Proc Natl Acad Sci U S A (1999) 1.87

Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J Virol (2010) 1.82

Characterization of recombinant human interleukin-2 with micromethods. J Chromatogr (1985) 1.76

Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. J Virol (2010) 1.60

Cell Surface Proteomic Map of HIV Infection Reveals Antagonism of Amino Acid Metabolism by Vpu and Nef. Cell Host Microbe (2015) 1.58

Expression, purification, and activities of full-length and truncated versions of the integral membrane protein Vpu from HIV-1. Protein Sci (2002) 1.54

Use of a novel GFP reporter cell line to examine replication capacity of CXCR4- and CCR5-tropic HIV-1 by flow cytometry. J Virol Methods (2005) 1.51

An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus. J Virol (2000) 1.44

Deletion of the vpu sequences prior to the env in a simian-human immunodeficiency virus results in enhanced Env precursor synthesis but is less pathogenic for pig-tailed macaques. Virology (2002) 1.34

Structural and functional analysis of the membrane-spanning domain of the human immunodeficiency virus type 1 Vpu protein. Virology (1998) 1.33

Regulation of virus release by the macrophage-tropic human immunodeficiency virus type 1 AD8 isolate is redundant and can be controlled by either Vpu or Env. J Virol (1999) 1.31

Do Vpu and Vpr of human immunodeficiency virus type 1 and NB of influenza B virus have ion channel activities in the viral life cycles? Virology (1997) 1.29

Reduced replication capacity of NL4-3 recombinant viruses encoding reverse transcriptase-integrase sequences from HIV-1 elite controllers. J Acquir Immune Defic Syndr (2011) 1.27

Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. Proc Natl Acad Sci U S A (2014) 1.26

Modulation of HIV-1-host interaction: role of the Vpu accessory protein. Retrovirology (2010) 1.26

Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral Res (2013) 1.25

Amiloride derivatives block ion channel activity and enhancement of virus-like particle budding caused by HIV-1 protein Vpu. Eur Biophys J (2002) 1.24

HIV Nef and Vpu protect HIV-infected CD4+ T cells from antibody-mediated cell lysis through down-modulation of CD4 and BST2. Retrovirology (2014) 1.22

Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals. PLoS Pathog (2014) 1.14

Cell surface down-modulation of CD4 after infection by HIV-1. FASEB J (1994) 1.06

Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling. J Virol (2012) 1.05

Transmembrane domain determinants of CD4 Downregulation by HIV-1 Vpu. J Virol (2011) 1.01

Potential new anti-human immunodeficiency virus type 1 compounds depress virus replication in cultured human macrophages. Antimicrob Agents Chemother (2004) 0.99

Oligomerization state and supramolecular structure of the HIV-1 Vpu protein transmembrane segment in phospholipid bilayers. Protein Sci (2010) 0.97

Guanylate Binding Protein (GBP) 5 Is an Interferon-Inducible Inhibitor of HIV-1 Infectivity. Cell Host Microbe (2016) 0.96

Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages. Antimicrob Agents Chemother (2009) 0.96

HIV-1 Vpu - an ion channel in search of a job. Biochim Biophys Acta (2013) 0.91

Ion channel activity of HIV-1 Vpu is dispensable for counteraction of CD317. Virology (2011) 0.91

Mechanism of HIV antiretroviral drugs progress toward drug resistance. Fundam Clin Pharmacol (2011) 0.90

Biophysical characterization of Vpu from HIV-1 suggests a channel-pore dualism. Proteins (2008) 0.89

HIV-1 mutates to evade IFITM1 restriction. Virology (2014) 0.89

Effects of Vpu expression on Xenopus oocyte membrane conductance. Virology (1998) 0.88

The HIV-1 Vpu viroporin inhibitor BIT225 does not affect Vpu-mediated tetherin antagonism. PLoS One (2011) 0.88

Interaction of amiloride and one of its derivatives with Vpu from HIV-1: a molecular dynamics simulation. FEBS Lett (2004) 0.85

A Phase 1b/2a study of the safety, pharmacokinetics and antiviral activity of BIT225 in patients with HIV-1 infection. J Antimicrob Chemother (2015) 0.84

Role of HIV-1 Envelope Glycoproteins Conformation and Accessory Proteins on ADCC Responses. Curr HIV Res (2016) 0.84

Immunosuppressive and cytotoxic therapy: pharmacology, toxicities, and monitoring. Semin Respir Crit Care Med (2011) 0.83

Genistein as antiviral drug against HIV ion channel. Planta Med (2014) 0.83

Viral channel proteins in intracellular protein-protein communication: Vpu of HIV-1, E5 of HPV16 and p7 of HCV. Biochim Biophys Acta (2013) 0.82

Drug-protein interaction with Vpu from HIV-1: proposing binding sites for amiloride and one of its derivatives. Anal Bioanal Chem (2006) 0.81

Viral targets of acylguanidines. Drug Discov Today (2012) 0.78

Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses. PLoS One (2015) 0.78

Ligand-protein docking studies of potential HIV-1 drug compounds using the algorithm FlexX. Anal Bioanal Chem (2010) 0.77

Screening of the Pan-African natural product library identifies ixoratannin A-2 and boldine as novel HIV-1 inhibitors. PLoS One (2015) 0.76

Probing interactions of Vpu from HIV-1 with amiloride-based compounds. Biochim Biophys Acta (2015) 0.76

Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors Derived from Hexamethylene Amiloride. Mol Pharmacol (2016) 0.76

Impaired Nef function is associated with early control of HIV-1 viremia. J Virol (2014) 0.86

Consequences of HLA-B*13-Associated Escape Mutations on HIV-1 Replication and Nef Function. J Virol (2015) 0.77

Subtype-Specific Differences in Gag-Protease-Driven Replication Capacity are Consistent with Inter-Subtype Differences in HIV-1 Disease Progression. J Virol (2017) 0.75

Relative resistance of MHC-B to Nef-mediated downregulation is conserved among primate lentiviruses and influences antiviral T cell responses in HIV-1-infected individuals. J Virol (2017) 0.75

Weaker HLA footprints on HIV in the unique and highly genetically admixed host population of Mexico. J Virol (2017) 0.75

Impaired Downregulation of NKG2D Ligands by Nef Proteins from Elite Controllers Sensitizes HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. J Virol (2017) 0.75

Mother-to-Child HIV Transmission Bottleneck Selects for Consensus Virus with Lower Gag-Protease-driven Replication Capacity. J Virol (2017) 0.75